MedPath

Effects of Rosiglitazone on Serum Ghrelin and Peptide YY Levels

Phase 4
Completed
Conditions
Type 2 Diabetes Mellitus
Obesity
Registration Number
NCT00522470
Lead Sponsor
Baskent University
Brief Summary

We aimed to evaluate the effects of rosiglitazone on serum ghrelin and peptide yy levels in diabetic women.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
Not specified
Inclusion Criteria
  • newly diagnosed, drug naive women with type 2 diabetes
Read More
Exclusion Criteria
  • presence of severe cardiovascular disease (eg, New York Heart Association class III or IV congestive heart failure or a history of myocardial infarction or stroke)
  • presence of thyroid, pituitary, nutritional, hepatic, renal, or neoplastic disorders
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Baskent University Hospital Department of Endocrinology

🇹🇷

Ankara, Bahçelievler, Turkey

© Copyright 2025. All Rights Reserved by MedPath